<p>Bicycle Therapeutics (NASDAQ:BCYC - 獲取免費報告) 預計將在 2025 年 2 月 24 日星期二市場開盤前發佈其 2025 年第四季度財報。分析師預計該公司將在本季度宣佈每股收益為（$1.00）。投資者可以訪問該公司即將發佈的 2025 年第四季度財報頁面，以獲取關於定於 2026 年 2 月 27 日星期五上午 2:00（東部時間）的電話會議的最新信息。</p>
<p>獲取 <strong>Bicycle Therapeutics</strong> 的提醒：</p>
<h2>Bicycle Therapeutics 股票表現</h2>
<p>BCYC 的股票在星期二以$5.24 開盤。該公司的市值為 3.635 億美元，市盈率為-1.45，貝塔值為 1.63。該公司的 50 日移動平均價格為$6.60，200 日移動平均價格為$7.10。Bicycle Therapeutics 的 52 周低點為$5.18，52 周高點為$13.11。</p>
<h2>Bicycle Therapeutics 內部活動</h2>
<p>在相關消息中，首席財務官 Alethia Young 於 1 月 5 日星期一出售了 4,334 股公司的股票。股票以平均價格$6.49 出售，總價值為$28,127.66。交易後，首席財務官直接持有 87,081 股公司股票，估值約為$565,155.69。這筆交易代表其持股減少了 4.74%。該交易已在向 SEC 提交的文件中披露，具體內容可通過此鏈接查看。此外，首席執行官 Kevin Lee 於 1 月 5 日星期一出售了 10,989 股公司的股票。股票以平均價格$6.46 出售，總交易額為$70,988.94。交易後，首席執行官直接持有 618,996 股公司的股票，估值約為$3,998,714.16。這代表其持股減少了 1.74%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士出售了 38,029 股公司股票，價值為$251,966。公司內部人士持有 8.50% 的公司股票。</p>
<h2>對 Bicycle Therapeutics 的對沖基金看法</h2>
<p>一些機構投資者最近對該公司的持倉進行了調整。Brooklyn Investment Group 在第四季度購買了 Bicycle Therapeutics 的新股份，價值約為$69,000。Ausdal Financial Partners Inc.在第二季度收購了 Bicycle Therapeutics 的新股份，價值$70,000。Vontobel Holding Ltd.在第四季度購買了 Bicycle Therapeutics 的新股份，價值$71,000。Sei Investments Co.在第二季度收購了 Bicycle Therapeutics 的新股份，價值$74,000。最後，Ameriprise Financial Inc.在第二季度購買了 Bicycle Therapeutics 的新股份，價值$86,000。目前 86.15% 的股票由機構投資者持有。</p>
<h2>分析師評級變動</h2>
<p>一些股票分析師最近對 BCYC 股票發表了看法。加拿大皇家銀行在 10 月 31 日星期五的研究報告中重申了 “行業表現” 評級，並將 Bicycle Therapeutics 的目標價下調至$11.00（之前為$27.00）。Weiss Ratings 在 12 月 22 日星期一的研究報告中重申了對 Bicycle Therapeutics 的 “賣出（e+）” 評級。Truist Financial 在 11 月 24 日星期一的研究報告中開始覆蓋 Bicycle Therapeutics。他們設定了 “持有” 評級和$10.00 的目標價。花旗集團在 10 月 31 日星期五的研究報告中重新發布了對 Bicycle Therapeutics 的 “跑贏大盤” 評級。最後，JMP Securities 在 10 月 31 日星期五的報告中設定了 Bicycle Therapeutics 的目標價為$12.00。七位投資分析師對該股票給予了買入評級，四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Bicycle Therapeutics 目前的共識評級為 “適度買入”，共識目標價為$20.20。</p>
<p><strong>獲取我們最新的 BCYC 股票報告</strong></p>
<h2>Bicycle Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Bicycle Therapeutics plc 是一家臨牀階段的生物技術公司，專注於基於其專有的雙環肽平台發現和開發新型肽類治療藥物。該公司的核心技術利用約束肽結構，結合了生物製劑的結合特異性和小分子的良好組織穿透特性。這種方法旨在生成具有高度選擇性的藥物候選者，潛在應用於包括腫瘤學、神經科學和免疫學等多個治療領域。</p>
<p>Bicycle Therapeutics 維持着多樣化的內部開發項目管道，以及與領先製藥合作伙伴的合作。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Bicycle Therapeutics</li>
<li>你的銀行賬户不再安全</li>
<li>Nvidia 首席執行官發出大膽的特斯拉呼籲</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>這隻$15 的股票可能會成為 2026 年的第一隻股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNZQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNZQw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Bicycle Therapeutics 嗎？</h2>
<p>在你考慮 Bicycle Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Bicycle Therapeutics 並不在名單上。</p>
<p>雖然 Bicycle Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

動態生物技術與基因組 ETF - Invesco

醫藥突破 ETF - ALPS

紐交所高增長板生物技術指數 ETF - First Trust

BCYC

標普生物技術 ETF - SPDR

生物科技 ETF - VanEck Vectors

2 倍做多納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

BTTX

<p>Bicycle Therapeutics（納斯達克代碼：BCYC）定於 2 月 24 日發佈 2025 年第四季度財報，分析師預計每股虧損 1.00 美元。該公司股票開盤價為 5.24 美元，市值為 3.635 億美元。最近的內部交易包括首席財務官 Alethia Young 和首席執行官 Kevin Lee，他們分別以約 6.49 美元和 6.46 美元的價格出售了股票。機構投資者持有 86.15% 的股份，分析師對該股票的共識評級為 “適度買入”，目標價為 20.20 美元</p>

<p>Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) is anticipated to issue its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter. Investors may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 2:00 AM ET.</p>
<div class="lb-trans"><p>Bicycle Therapeutics (NASDAQ:BCYC - 獲取免費報告) 預計將在 2025 年 2 月 24 日星期二市場開盤前發佈其 2025 年第四季度財報。分析師預計該公司將在本季度宣佈每股收益為（$1.00）。投資者可以訪問該公司即將發佈的 2025 年第四季度財報頁面，以獲取關於定於 2026 年 2 月 27 日星期五上午 2:00（東部時間）的電話會議的最新信息。</p>
</div><p>Get <strong>Bicycle Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Bicycle Therapeutics</strong> 的提醒：</p>
</div><h2>Bicycle Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 股票表現</h2>
</div><p>Shares of BCYC opened at $5.24 on Tuesday. The company has a market capitalization of $363.50 million, a PE ratio of -1.45 and a beta of 1.63. The company's 50 day moving average price is $6.60 and its 200 day moving average price is $7.10. Bicycle Therapeutics has a 52 week low of $5.18 and a 52 week high of $13.11.</p>
<div class="lb-trans"><p>BCYC 的股票在星期二以$5.24 開盤。該公司的市值為 3.635 億美元，市盈率為-1.45，貝塔值為 1.63。該公司的 50 日移動平均價格為$6.60，200 日移動平均價格為$7.10。Bicycle Therapeutics 的 52 周低點為$5.18，52 周高點為$13.11。</p>
</div><h2>Insider Activity at Bicycle Therapeutics</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 內部活動</h2>
</div><p>In related news, CFO Alethia Young sold 4,334 shares of the firm's stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the transaction, the chief financial officer directly owned 87,081 shares in the company, valued at approximately $565,155.69. This trade represents a 4.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin Lee sold 10,989 shares of the business's stock in a transaction on Monday, January 5th. The stock was sold at an average price of $6.46, for a total transaction of $70,988.94. Following the transaction, the chief executive officer directly owned 618,996 shares of the company's stock, valued at approximately $3,998,714.16. This represents a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 38,029 shares of company stock valued at $251,966. Corporate insiders own 8.50% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席財務官 Alethia Young 於 1 月 5 日星期一出售了 4,334 股公司的股票。股票以平均價格$6.49 出售，總價值為$28,127.66。交易後，首席財務官直接持有 87,081 股公司股票，估值約為$565,155.69。這筆交易代表其持股減少了 4.74%。該交易已在向 SEC 提交的文件中披露，具體內容可通過此鏈接查看。此外，首席執行官 Kevin Lee 於 1 月 5 日星期一出售了 10,989 股公司的股票。股票以平均價格$6.46 出售，總交易額為$70,988.94。交易後，首席執行官直接持有 618,996 股公司的股票，估值約為$3,998,714.16。這代表其持股減少了 1.74%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士出售了 38,029 股公司股票，價值為$251,966。公司內部人士持有 8.50% 的公司股票。</p>
</div><h2>Hedge Funds Weigh In On Bicycle Therapeutics</h2>
<div class="lb-trans"><h2>對 Bicycle Therapeutics 的對沖基金看法</h2>
</div><p>A number of institutional investors have recently made changes to their positions in the business. Brooklyn Investment Group bought a new stake in Bicycle Therapeutics during the 4th quarter valued at approximately $69,000. Ausdal Financial Partners Inc. acquired a new stake in shares of Bicycle Therapeutics in the second quarter worth $70,000. Vontobel Holding Ltd. bought a new position in Bicycle Therapeutics during the fourth quarter worth $71,000. Sei Investments Co. acquired a new position in Bicycle Therapeutics during the 2nd quarter valued at $74,000. Finally, Ameriprise Financial Inc. bought a new stake in Bicycle Therapeutics in the 2nd quarter valued at $86,000. 86.15% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者最近對該公司的持倉進行了調整。Brooklyn Investment Group 在第四季度購買了 Bicycle Therapeutics 的新股份，價值約為$69,000。Ausdal Financial Partners Inc.在第二季度收購了 Bicycle Therapeutics 的新股份，價值$70,000。Vontobel Holding Ltd.在第四季度購買了 Bicycle Therapeutics 的新股份，價值$71,000。Sei Investments Co.在第二季度收購了 Bicycle Therapeutics 的新股份，價值$74,000。最後，Ameriprise Financial Inc.在第二季度購買了 Bicycle Therapeutics 的新股份，價值$86,000。目前 86.15% 的股票由機構投資者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of equities analysts have recently weighed in on BCYC shares. Royal Bank Of Canada reaffirmed a &#34;sector perform&#34; rating and issued a $11.00 price target (down from $27.00) on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Truist Financial initiated coverage on Bicycle Therapeutics in a research note on Monday, November 24th. They set a &#34;hold&#34; rating and a $10.00 price target for the company. Citigroup reissued an &#34;outperform&#34; rating on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Finally, JMP Securities set a $12.00 price objective on Bicycle Therapeutics in a report on Friday, October 31st. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Bicycle Therapeutics presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $20.20.</p>
<div class="lb-trans"><p>一些股票分析師最近對 BCYC 股票發表了看法。加拿大皇家銀行在 10 月 31 日星期五的研究報告中重申了 “行業表現” 評級，並將 Bicycle Therapeutics 的目標價下調至$11.00（之前為$27.00）。Weiss Ratings 在 12 月 22 日星期一的研究報告中重申了對 Bicycle Therapeutics 的 “賣出（e+）” 評級。Truist Financial 在 11 月 24 日星期一的研究報告中開始覆蓋 Bicycle Therapeutics。他們設定了 “持有” 評級和$10.00 的目標價。花旗集團在 10 月 31 日星期五的研究報告中重新發布了對 Bicycle Therapeutics 的 “跑贏大盤” 評級。最後，JMP Securities 在 10 月 31 日星期五的報告中設定了 Bicycle Therapeutics 的目標價為$12.00。七位投資分析師對該股票給予了買入評級，四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Bicycle Therapeutics 目前的共識評級為 “適度買入”，共識目標價為$20.20。</p>
</div><p><strong>Get Our Latest Stock Report on BCYC</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 BCYC 股票報告</strong></p>
</div><h2>Bicycle Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company's core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.</p>
<div class="lb-trans"><p>Bicycle Therapeutics plc 是一家臨牀階段的生物技術公司，專注於基於其專有的雙環肽平台發現和開發新型肽類治療藥物。該公司的核心技術利用約束肽結構，結合了生物製劑的結合特異性和小分子的良好組織穿透特性。這種方法旨在生成具有高度選擇性的藥物候選者，潛在應用於包括腫瘤學、神經科學和免疫學等多個治療領域。</p>
</div><p>Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.</p>
<div class="lb-trans"><p>Bicycle Therapeutics 維持着多樣化的內部開發項目管道，以及與領先製藥合作伙伴的合作。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Bicycle Therapeutics</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Bicycle Therapeutics</li>
<li>你的銀行賬户不再安全</li>
<li>Nvidia 首席執行官發出大膽的特斯拉呼籲</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>這隻$15 的股票可能會成為 2026 年的第一隻股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNZQw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=BCYC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bicycle Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Bicycle Therapeutics 嗎？</h2>
</div><p>Before you consider Bicycle Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Bicycle Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Bicycle Therapeutics 並不在名單上。</p>
</div><p>While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Bicycle Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Bicycle Therapeutics (BCYC) 預計將在週二發佈季度財報